iX Biopharma

Continue to 'buy' iX Biopharma as expanded product use and capacity should provide stock catalysts: PhillipCapital - THE EDGE SINGAPORE

Broker's Calls

Continue to 'buy' iX Biopharma as expanded product use and capacity should provide stock catalysts: PhillipCapital

PhillipCapital has maintained its target price of 44.5 cents for iX Biopharma.
iX Biopharma to expand wafer production capacity at Australian facility - THE EDGE SINGAPORE

Company in the news

iX Biopharma to expand wafer production capacity at Australian facility

New freeze-dry equipment will boost the production of its WaferiX wafers up to six times its current capacity.
Broker's Digest: Samudera, Raffles Medical, Multi-Chem, iX Biopharma, Hong Leong Asia - THE EDGE SINGAPORE

Broker's Calls

Broker's Digest: Samudera, Raffles Medical, Multi-Chem, iX Biopharma, Hong Leong Asia

See the analysts' recommendations and target prices here.
PhillipCapital 'remains confident' in iX Biopharma’s growth prospects upon China agreement - THE EDGE SINGAPORE

Broker's Calls

PhillipCapital 'remains confident' in iX Biopharma’s growth prospects upon China agreement

PhillipCapital has kept its "buy" recommendation with the same target price of 44.5 cents.
iX Biopharma enters agreement with Chinese pharmaceutical distributor to tap China market - THE EDGE SINGAPORE

Deals, joint ventures & alliances

iX Biopharma enters agreement with Chinese pharmaceutical distributor to tap China market

iX Biopharma has partnered with China Resources Pharmaceutical Group to distribute products in China.
973 Brokers' Digest - THE EDGE SINGAPORE

Broker's Calls

973 Brokers' Digest

Take a look at these six stocks this week, including DBS, Starhub and ST Engineering.
iX Biopharma remains a 'buy' from PhillipCapital despite $2.8 million net loss in 1H21 - THE EDGE SINGAPORE

Broker's Calls

iX Biopharma remains a 'buy' from PhillipCapital despite $2.8 million net loss in 1H21

PhillipCapital is maintaining its “buy” call on iX Biopharma, but at a lower target price of 44.5 cents.
IX Biopharma appoints Eva Tan as CCO  - THE EDGE SINGAPORE

New appointments

IX Biopharma appoints Eva Tan as CCO

Speciality pharmaceutical company iX Biopharma has appointed Eva Tan as its new chief commercial officer.
PhillipCapital eyes year-end STI at 3,200 - THE EDGE SINGAPORE

Positioning for the recovery

PhillipCapital eyes year-end STI at 3,200

“Investors are positioning ahead of the expected normality to pre-Covid-19 economic conditions," says PhillipCapital.
iX Biopharma obtains approval and registration of male erectile dysfunction drug in Singapore - THE EDGE SINGAPORE

Company in the news

iX Biopharma obtains approval and registration of male erectile dysfunction drug in Singapore

The drug will be supplied via licensed medical practitioners in Singapore.
×